Our data revealed that decitabine treatment inhibited tumor growth and resulted in DNA hypomethylation that was associated with 3D epigenome remodeling, gain in ER binding and activation of ER-mediated transcription, highlighting the potential of epigenetic therapy for the treatment of ER+ endocrine-resistant breast cancer. This evidence concerns the gene ESR1 and breast cancer.